Retatrutide in Cam Ranh: Understanding Treatment Adherence, Discontinuation, and Long-Term Outcomes
Research Snapshot
Research question: How should treatment adherence, treatment discontinuation, and long-term outcomes be interpreted in retatrutide research?
Featured answer: Adherence affects how consistently participants receive a study treatment, while discontinuation describes stopping that treatment before or at the end of the planned period. Both can influence how trial results are interpreted. In the 2023 Phase 2 retatrutide trial, discontinuation because of adverse events occurred in 6% to 16% of participants in the retatrutide groups, compared with none in the placebo group. In the sponsor-reported Phase 3 TRIUMPH-1 results released in May 2026, discontinuation because of adverse events ranged from approximately 4% to 11% across retatrutide groups, compared with about 5% for placebo. These findings describe trial-period tolerability, not the long-term outcome after retatrutide is stopped.
Compound: Retatrutide (LY3437943), an investigational triple GIP, GLP-1, and glucagon receptor agonist.
Evidence base: Published Phase 2 clinical-trial findings, sponsor-reported Phase 3 findings, and research on treatment withdrawal involving other obesity medicines.
Key evidence gap: Outcomes after retatrutide discontinuation require direct follow-up. Results from semaglutide or other incretin-based medicines can provide context but cannot establish the exact post-treatment trajectory of retatrutide.
Key Takeaways
- Adherence and persistence are different. Adherence concerns how closely treatment is followed; persistence concerns how long treatment continues before discontinuation.
- Discontinuation is an important clinical-trial outcome. It can reflect adverse events, perceived lack of benefit, participant preference, protocol requirements, or practical barriers.
- Gastrointestinal adverse events matter. In the Phase 2 retatrutide trial, nausea, diarrhea, vomiting, and constipation were common, particularly during dose escalation, and were among the main reasons for stopping treatment.
- Discontinuation rates vary across trials and doses. They should be interpreted alongside study design, treatment duration, dose escalation, and how adverse events were defined.
- Stopping treatment and stopping trial participation are not the same. A participant may stop receiving the assigned medicine but continue attending follow-up assessments.
- Long-term outcomes require separate evidence. On-treatment weight loss does not show how much weight will be regained after retatrutide is discontinued.
- Evidence from other medicines is contextual, not interchangeable. Withdrawal studies involving semaglutide and other GLP-1 receptor agonists do not directly predict retatrutide outcomes.
- Retatrutide remains investigational. Trial results should not be treated as instructions for self-directed use or as verification of products sold outside authorized research.
1. Understanding Adherence, Persistence, and Discontinuation
Discussions of obesity treatment often focus on how much weight participants lose. However, efficacy is only one part of a medicine’s overall clinical profile. Researchers must also understand whether participants can continue treatment, whether they follow the assigned regimen, why some stop treatment, and what happens to their health outcomes over time.
Three terms are especially important when interpreting retatrutide research.
| Term | Meaning | Why it matters |
|---|---|---|
| Treatment adherence | How closely a participant follows the assigned treatment regimen, as defined by the study. | Irregular exposure can affect the interpretation of treatment response and safety observations. |
| Treatment persistence | How long a participant continues the assigned treatment before stopping. | Persistence helps describe whether a treatment can be maintained throughout the planned study period. |
| Treatment discontinuation | Stopping the assigned medicine, temporarily or permanently according to the study’s definitions. | The reason for stopping can affect safety assessment, outcome analysis, and interpretation of treatment effectiveness. |
| Study withdrawal | Leaving the research study or ending participation in follow-up. | If follow-up data are missing, researchers may have less information about later outcomes. |
These concepts overlap, but they are not interchangeable. A participant might discontinue the assigned medicine while continuing study visits. Another participant might stop attending visits, leaving researchers with incomplete information about subsequent weight change or adverse events.
Consequently, a discontinuation percentage should never be interpreted without checking what the trial counted, why participants stopped, and whether those participants continued to be assessed.
2. Why Adherence Matters in Retatrutide Trials
Retatrutide is being investigated as a triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors. These signaling pathways are involved in metabolic regulation, and the compound has demonstrated substantial mean weight reduction in clinical trials. However, the size of a treatment effect is only one component of the evidence.
To understand the results, researchers need to know whether participants received the assigned treatment as intended, whether they completed the planned dose-escalation schedule, and whether treatment interruptions occurred. These details help distinguish the effect of assignment to a treatment strategy from the response observed among participants who remained on treatment.
In randomized trials, the primary efficacy analysis often aims to preserve the benefits of randomization by analyzing participants according to their assigned treatment under a prespecified statistical framework. Other analyses may focus on an efficacy scenario with different assumptions about treatment discontinuation or other events after randomization.
These approaches answer different questions. An estimate based on treatment assignment can help inform the expected effect of a treatment strategy under trial conditions, while an efficacy-focused estimate may address a different question about treatment response under specified assumptions. Neither should be interpreted without understanding the analysis plan.
A trial may demonstrate substantial average weight reduction while also recording treatment discontinuations. These findings are not contradictory. Efficacy describes a treatment outcome under a specified analysis, whereas persistence describes how long participants continued treatment. A complete assessment considers both.
3. What the Phase 2 Retatrutide Trial Revealed About Discontinuation
The Phase 2 trial published by Jastreboff and colleagues in 2023 enrolled 338 adults with obesity or overweight plus a weight-related condition. Participants were randomized to receive different retatrutide regimens or placebo and were followed during a 48-week treatment period.
At week 48, the trial reported substantial mean weight reduction in the retatrutide groups. However, adverse events were also observed, particularly gastrointestinal events such as nausea, diarrhea, vomiting, and constipation.
The published report stated that discontinuation of retatrutide because of adverse events occurred in approximately 6% to 16% of participants across the retatrutide groups, compared with none in the placebo group. Gastrointestinal events were the most common adverse events leading to discontinuation. The investigators also reported that these events occurred more frequently at higher doses and were concentrated particularly around dose escalation.
The trial explored whether a lower initial dose could improve tolerability. Gastrointestinal adverse events were partially mitigated by starting at 2 mg rather than 4 mg in the regimens studied. This is a finding about the research protocol, not a recommendation for individuals to initiate or modify treatment independently.
These observations demonstrate why weight-loss efficacy and tolerability must be assessed together. A substantial mean weight reduction does not eliminate the importance of adverse events or the possibility that some participants will find treatment difficult to continue.
4. What Phase 3 TRIUMPH-1 Adds to the Evidence
In May 2026, Eli Lilly announced topline results from TRIUMPH-1, a Phase 3 trial evaluating retatrutide in adults with obesity or overweight plus at least one weight-related condition, without diabetes. The sponsor reported results from 2,339 participants over 80 weeks. Subsequent peer-reviewed publication provides a more detailed basis for interpreting the study’s efficacy and safety findings.
In the sponsor’s report, discontinuation because of adverse events occurred in approximately 4% to 11% of participants across the retatrutide treatment groups, compared with about 5% in the placebo group. Gastrointestinal adverse events were the most common reason for discontinuation. The reported proportion of participants discontinuing because of gastrointestinal adverse events ranged from 2.2% to 4.6% in the retatrutide groups, compared with 1.2% in the placebo group.
| Evidence source | Reported discontinuation finding | Interpretation |
|---|---|---|
| Phase 2 trial, 2023 | 6%–16% of participants receiving retatrutide discontinued because of adverse events; none in the placebo group. | Early evidence that adverse events, particularly gastrointestinal events, affected treatment continuation. |
| Phase 3 TRIUMPH-1, sponsor topline report, 2026 | Approximately 4%–11% across retatrutide groups, compared with approximately 5% for placebo. | Larger, longer-duration evidence that allows a broader assessment of treatment tolerability. |
| Phase 3 TRIUMPH-1, gastrointestinal adverse events | Approximately 2.2%–4.6% across retatrutide groups, compared with 1.2% for placebo. | Gastrointestinal events remained an important reason for treatment discontinuation. |
Important limitation: The Phase 2 and Phase 3 ranges should not be compared as though they came from an identical protocol. The trials differed in design, dose regimens, participant populations, follow-up, and other characteristics. The sponsor’s topline report is useful evidence, but it should be distinguished from the detailed methods and analyses in the peer-reviewed publication.
5. Why Participants May Discontinue Treatment
Discontinuation is not a single clinical event with a single explanation. Researchers distinguish between stopping because of adverse events and stopping for other reasons. The reason matters because each pathway has different implications for tolerability, effectiveness, and the interpretation of follow-up data.
| Possible reason | What researchers need to assess | Why it matters |
|---|---|---|
| Adverse events | Type, severity, timing, seriousness, and relationship to treatment. | Helps characterize tolerability and the observed safety profile. |
| Perceived lack of benefit | The participant’s expectations, observed response, and timing of discontinuation. | Can affect persistence and the practical interpretation of treatment effectiveness. |
| Protocol or investigator decision | Whether a predefined stopping criterion or safety concern was met. | A protocol-directed stop is not equivalent to a participant independently choosing to stop. |
| Participant preference | The reason for withdrawal and whether follow-up continues. | Helps distinguish stopping treatment from leaving the study. |
| Practical or access barriers | The role of study logistics, cost, availability, or other barriers where data are collected. | Can affect treatment persistence independently of pharmacological efficacy. |
Not all these reasons are necessarily established or quantified in the published retatrutide trials. They are general categories used to explain why discontinuation data require context. The available evidence should be reported as documented rather than assuming that all participants stopped for the same reason.
6. Adverse Events, Dose Escalation, and Treatment Continuation
In the Phase 2 retatrutide study, gastrointestinal events were the most frequently reported adverse events. They included nausea, diarrhea, vomiting, and constipation. The publication described these events as generally mild to moderate, dose-related, and more frequent during dose escalation. The study also reported dose-dependent increases in heart rate that peaked around week 24 and declined thereafter.
These findings help explain why tolerability is central to adherence and persistence research. A participant’s ability to remain in a trial depends not only on the treatment’s observed effect but also on the adverse events experienced and the study’s protocol for monitoring and managing them.
However, these results do not establish that all participants will experience the same adverse events or that the same pattern will occur outside the study. Clinical trials use defined eligibility criteria, monitoring, and treatment procedures. A product obtained outside an authorized trial may not have the same identity, quality, or safety profile as the investigational material used by researchers.
For this reason, the appropriate interpretation is descriptive: researchers observed certain adverse events and discontinuation patterns under specific trial conditions. Those data do not support self-directed dosing changes, restarting after a treatment interruption, or using an investigational product without qualified clinical oversight.
7. What Happens to Weight After Treatment Discontinuation?
This is a central question in obesity pharmacotherapy, but it must be separated from evidence about weight loss during active treatment.
Retatrutide trials have demonstrated substantial mean weight reduction over defined treatment periods. Yet a trial’s on-treatment endpoint does not, by itself, establish how much weight participants will regain after stopping retatrutide. To answer that question directly, investigators need follow-up data collected after discontinuation, with clearly defined endpoints and sufficient observation time.
Research involving other medicines provides useful context. In the STEP 1 semaglutide trial extension, participants regained a substantial proportion of previously lost weight during the year after semaglutide and the structured lifestyle intervention were discontinued. This finding illustrates that stopping an effective obesity treatment can be followed by weight regain, but it does not establish the magnitude or timing of weight regain after retatrutide.
A 2026 systematic review and nonlinear meta-regression of GLP-1 receptor agonist withdrawal studies also reported that weight generally rebounded after treatment cessation. The authors estimated that approximately 60% of the weight lost during treatment was regained by one year after cessation in their analysis. That estimate is specific to the studies and medicines included in the review and must not be presented as a retatrutide-specific result.
Withdrawal studies involving semaglutide or other GLP-1 receptor agonists can inform the broader understanding of obesity treatment. They cannot tell us exactly how quickly or how much weight will be regained after retatrutide is stopped. A direct conclusion requires retatrutide-specific post-treatment data.
8. Long-Term Outcomes Extend Beyond Body Weight
Long-term treatment outcomes should not be reduced to a single body-weight percentage. Obesity research may evaluate metabolic markers, blood pressure, physical functioning, quality of life, cardiovascular outcomes, and the recurrence of weight-related complications. These outcomes can change on different timelines and may not all be measured in the same study.
The Phase 2 retatrutide publication reported changes in several exploratory measures in addition to body weight. For example, among participants who had prediabetes at baseline, 72% of those in the retatrutide groups had reverted to normoglycemia at week 48, compared with 22% in the placebo group. The publication also described changes in blood pressure and some quality-of-life measures.
These are trial findings during the treatment period. They should not be interpreted as proof that improvements will persist after treatment is discontinued. Nor do exploratory metabolic findings establish reductions in major cardiovascular events or other outcomes that require dedicated trials.
Long-term outcome assessment therefore needs to distinguish at least three periods:
- During treatment: changes in body weight, metabolic measures, tolerability, and other predefined outcomes.
- After discontinuation: changes in weight and health measures after participants stop receiving the investigational treatment.
- Longer-term follow-up: whether benefits, risks, or weight-related complications persist, recur, or change over a longer period.
Evidence from one period cannot automatically answer questions about another. An 80-week treatment result, for example, does not establish the outcome five years after treatment begins or one year after treatment ends.
9. How Discontinuation Can Affect Clinical-Trial Results
Discontinuation has methodological consequences as well as clinical significance. When participants stop treatment, researchers must decide how to analyze outcomes that occur after stopping, how to handle missing measurements, and which treatment effect the analysis is intended to estimate.
Three issues are particularly important:
- Missing outcome data: If participants stop attending follow-up visits, researchers may have less information about their later weight or health status. Statistical methods are needed to address missing measurements, but the assumptions behind those methods matter.
- Intercurrent events: Events such as treatment discontinuation can occur after randomization and affect how the treatment effect is defined. An estimand specifies how the analysis handles these events.
- Selection effects: Participants who remain on treatment may differ from those who discontinue. Analyses restricted to participants who complete treatment can therefore answer a different question from analyses that preserve the original randomized groups.
For readers, the practical lesson is to avoid assuming that every reported percentage represents the same group of participants under the same assumptions. A peer-reviewed paper’s methods and supplementary materials are often necessary to understand the denominator, handling of discontinuation, and interpretation of the final estimate.
10. What the Current Evidence Can and Cannot Establish
| Question | What the evidence supports | What remains uncertain |
|---|---|---|
| Can retatrutide reduce body weight during treatment? | Randomized Phase 2 and Phase 3 trials have reported substantial mean weight reduction during defined treatment periods. | The result an individual will experience and the response outside trial conditions. |
| Can adverse events lead to discontinuation? | Yes. Both Phase 2 and sponsor-reported Phase 3 data document treatment discontinuation because of adverse events. | How rates may differ across broader populations and future treatment settings. |
| Will weight be regained after stopping retatrutide? | Withdrawal research involving other incretin-based medicines indicates that weight regain can occur after cessation. | The exact magnitude, timing, and variability of weight regain after retatrutide discontinuation. |
| Will metabolic benefits persist after discontinuation? | Some metabolic improvements have been observed during retatrutide treatment. | The durability of retatrutide-specific benefits after treatment stops. |
| Is long-term safety fully established? | Trials provide safety observations over their defined follow-up periods. | All risks over many years, uncommon delayed events, and outcomes in populations not studied. |
11. How to Read Adherence and Discontinuation Headlines
When an article reports that a certain percentage of participants discontinued retatrutide, readers should check the following details:
- Identify the source. Is the figure from a peer-reviewed publication, a clinical-trial registry, or a sponsor announcement?
- Check the time period. Is the rate measured over 48 weeks, 80 weeks, or another follow-up period?
- Identify the reason. Does the figure refer specifically to adverse events, all-cause discontinuation, or withdrawal from study participation?
- Check the comparator. What was the corresponding rate in the placebo group?
- Review the dose groups. A pooled range may conceal differences between doses.
- Distinguish treatment discontinuation from study withdrawal. Participants may stop treatment and still contribute follow-up data.
- Review the analysis method. Determine how missing measurements and events after randomization were handled.
- Separate on-treatment results from post-treatment outcomes. A discontinuation rate does not tell readers what happened to participants’ weight after stopping.
Frequently Asked Questions
Adherence describes how closely a participant follows the assigned treatment regimen as defined by the trial. It helps researchers interpret treatment exposure, safety observations, and outcomes, but it is not the same as the length of time someone remains on treatment.
Discontinuation means stopping the assigned medicine. Study withdrawal means leaving the research study or ending participation in follow-up. A participant may stop treatment while continuing to attend study visits and provide outcome data.
The 2023 Phase 2 publication reported discontinuation because of adverse events in approximately 6% to 16% of participants across retatrutide groups, compared with none in the placebo group. Gastrointestinal events were the most common reasons for stopping treatment because of adverse events.
The sponsor’s May 2026 topline report described discontinuation because of adverse events in approximately 4% to 11% of participants across retatrutide groups, compared with approximately 5% in the placebo group. These sponsor-reported results should be interpreted in the context of the study’s design and the detailed published analysis.
Nausea, diarrhea, vomiting, and constipation were among the common adverse events. In the Phase 2 trial, gastrointestinal events were dose-related, occurred particularly during dose escalation, and were the most common adverse events leading to discontinuation.
No. Discontinuation is one safety-related measure, not a complete assessment of safety. Interpretation also requires adverse-event severity, serious adverse events, exposure duration, participant characteristics, and the limitations of the study population.
The available evidence discussed here does not establish the exact weight trajectory after retatrutide discontinuation. Research involving other incretin-based medicines shows that weight regain can occur after treatment stops, but those results cannot be used to quantify the outcome for retatrutide.
They can provide context about obesity treatment and weight regain after stopping medication, but they cannot directly predict the magnitude or timing of weight regain after retatrutide. Compound-specific post-treatment follow-up is needed.
No. Metabolic improvements observed during treatment are important findings, but their persistence after discontinuation and their effect on long-term clinical outcomes require separate evidence.
Discontinuation can affect how later outcomes are measured and interpreted. Different estimands use different assumptions about events after randomization, so readers should check the analysis method before comparing reported treatment effects.
Retatrutide remains investigational as of October 2026. Clinical-trial findings do not establish regulatory approval or verify the quality and safety of products marketed outside authorized research settings.
No. Trial results summarize defined study populations and are not personal predictions or location-specific estimates. The outcome for an individual cannot be inferred from a group average alone.
Related Articles and Research Resources
- Vietnam Peptides Knowledge Hub — educational resources covering peptide science and clinical research.
- Peptide Research FAQ — general information about peptide terminology, research, and product-related questions.
- Peptide Products Directory — product listings that should be evaluated separately from independent clinical evidence.
Related Research Products
Retatrutide 20 mg — Research Product Listing
This listing relates to the investigational compound discussed in this article. A commercial listing is not clinical evidence and does not verify regulatory approval, product identity, purity, potency, sterility, storage history, or equivalence to the material used in published trials. Retatrutide should not be treated as an approved self-directed weight-management treatment.
Tirzepatide 20 mg — Related Research Listing
Tirzepatide is a related incretin-based medicine with published clinical-trial evidence for obesity. It is a different compound from retatrutide, and evidence about one medicine should not be presented as direct evidence about the other.
Scientific References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526. DOI: 10.1056/NEJMoa2301972. PubMed: PMID 37366315.
- Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. Published September 29, 2026. DOI: 10.1056/NEJMoa2604169.
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Sponsor topline release, May 21, 2026. Official announcement. Sponsor-reported discontinuation figures should be distinguished from detailed peer-reviewed trial analyses.
- Wilding JPH, Batterham RL, Davies M, et al.; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553–1564. DOI: 10.1111/dom.14725. PubMed: PMID 35441470.
- Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. The Lancet eClinicalMedicine. 2026. Full text: PubMed Central. The pooled estimate concerns the medicines and studies included in that review, not retatrutide specifically.
- American Diabetes Association. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. Diabetes, Obesity, and Cardiometabolic CARE. 2025. DOI: 10.2337/doci25-0008.
Conclusion
Adherence, discontinuation, and long-term outcomes are related but distinct dimensions of retatrutide research. The Phase 2 trial documented treatment discontinuation because of adverse events, particularly gastrointestinal events, while sponsor-reported Phase 3 findings provide additional information about discontinuation during a longer study. These results help researchers assess tolerability, but they do not by themselves establish what happens to body weight or metabolic health after retatrutide is stopped.
Research involving semaglutide and other incretin-based medicines indicates that weight regain can occur after treatment cessation. That evidence provides context for obesity pharmacotherapy, but it cannot be used to predict the precise post-treatment course of retatrutide. Direct retatrutide-specific follow-up is needed to answer that question.
The most reliable interpretation keeps treatment exposure, reasons for discontinuation, analysis methods, and post-treatment outcomes separate. Retatrutide remains investigational, and the available trial findings should not be treated as a personal treatment recommendation or as evidence that products sold outside authorized research are equivalent to the material used in clinical trials.